Motilal Oswal initiated coverage on Molbio Diagnostics with a Buy rating and ₹1,800 target, implying 21% upside. The brokerage sees strong growth potential from decentralised molecular diagnostics, led by Molbio’s Truenat platform, which has 12,500+ devices across 90+ countries and 43 assays for 30 diseases.